Maybank downgrades Malaysia's Tan Chong Motor to ‘sell' amid widening losses, competition
[SINGAPORE] Maybank Investment Bank has downgraded Malaysia's Tan Chong Motor (TCM) to 'sell', from 'hold' previously, amid widening losses, weak product appeal and intensifying competition.
Despite the downgrade, Maybank maintained its target price for the Bursa-listed company at RM0.38, based on an unchanged 0.1 times its forecast book value for FY2025.
TCM is the franchise holder for Nissan in Malaysia and Indo-China, as well as Renault in Malaysia and MG in Vietnam.
In a report on Monday (May 26), Maybank analyst Loh Yan Jin cited increased downside risks following a recent rally in TCM's share price as the reasons for downgrading its call on the automotive company. The stock has climbed nearly 60 per cent from its 52-week low of RM0.29 to RM0.46 in recent months.
'We believe downside risks have increased following the recent rally in share price,' Loh said.
TCM reported a core net loss of RM44.5 million (S$13.5 million) for the first quarter of 2025, more than double the RM18.3 million loss recorded in the same period a year earlier.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
Commenting on TCM's widening year-on-year losses, Loh said the latest results were in line with Maybank's full-year forecast of a RM147.3 million loss, but came in below the consensus estimate of a RM129.4 million loss.
Revenue for Q1 2025 slipped 2 per cent to RM553 million, weighed down by continued weakness in Nissan sales, which plunged 21 per cent year on year to 1,811 units.
However, Loh said the weakness in Malaysia was partially offset by growth in TCM's overseas operations, including Vietnam, Cambodia, Laos and Myanmar.
On a quarter-on-quarter basis, TCM's Q1 2025 revenue rose 8.2 per cent from RM511.2 million in Q4 2024, supported by a 22 per cent increase in Nissan sales in Malaysia and higher vehicle assembly and manufacturing activity.
Loh attributed this to a rebound from 'seasonally softer' year-end sales, which had been affected by intense promotions and competing model launches.
As a result, core net loss for Q1 2025 narrowed by 29 per cent to RM44.5 million from RM62.9 million in Q4 2024.
'Looking ahead, we expect challenges in TCM's automotive segment to persist, underpinned by weak product appeal and intensifying market competition,' Loh said.
'Soft consumer sentiment and unattractive model launches will further weigh down its earnings.'
A key re-rating catalyst, she added, would be stronger sales from new product launches or contract assembly deals, but 'visibility remains limited for now'.
'Improved operational efficiencies and better inventory management could also help enhance margins and profitability,' she said.
As at 4 pm on Tuesday, shares of TCM are trading RM0.455.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
a day ago
- Business Times
Hong Kong-listed China Medical System seeks secondary listing on SGX
[SINGAPORE] Hong Kong-listed China Medical System (CMS) is seeking a secondary listing on the mainboard of the Singapore Exchange (SGX) in July this year. CMS is a specialty pharma with a focus on sales and marketing in China, with capabilities across the full lifecycle of drug development, from identifying clinical needs to research and development (R&D) regulatory approval, and commercialisation. It has been listed on the Stock Exchange of Hong Kong since 2010. The pharmaceutical company expects the secondary listing will help it deepen its presence in South-east Asia and 'tap into a new and sophisticated investor base in Singapore'. CMS said it is looking to replicate its success in South-east Asia – building on the proven track record attained in China's pharmaceutical industry. 'This region, with a population of nearly 700 million, is experiencing surging pharmaceutical demand due to rapid economic growth, the rise of the middle class, ageing population, and the increasing burden of non-infectious diseases,' it said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Its financial performance in 2023 and 2024 were hit by China's volume-based procurement (VBP) policy – three of its products were included in the VBP list. This policy aims to lower the prices of drugs with generic competition, by guaranteeing certain procurement volumes from public hospitals at significantly reduced prices through a bidding process. But CMS had a top-line rebound in H2 2024, driven by progress in commercialising innovative drugs and the continued growth of non-VBP exclusive products. The company moved towards innovative drugs, given that they typically enjoy a pricing advantage due to their exclusiveness, novelty and quality, and are supported by favourable government policies. It expects growth momentum will accelerate on the back of the replenishment of its pipeline of innovative drugs to about 40 products as at Dec 31, 2024. It noted four key platforms to scale its pharmaceutical ecosystem across Asia-Pacific. CMS R&D is involved in drug discovery and development targeting global markets, while PharmaGend is a development and manufacturing platform for regional manufacturing and supply. It also has Rxilient Health, a Singapore-headquartered entity focused on registration and commercialisation in South-east Asia and a Singapore venture arm, which makes strategic investments to support regional pharma innovation. In a statement on Jun 24, CMS said the proposed listing will not involve issuance of new shares, and the shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. Singapore is its regional headquarters for its South-east Asia and Middle East business, the company said. The announcement follows the news of several new listings on SGX – software services provider Info-Tech Systems, a data centre real estate investment trust (Reit) by Japanese telco Nippon Telegraph and Telephone (NTT), and a spin-off of mainboard-listed construction company Lum Chang Holdings' interior fit-out business. Info-Tech Systems, whose shares are expected to begin trading on Jul 4, is the first SGX mainboard listing in two years. NTT DC Reit, which will have a portfolio of six of NTT's data centre assets, will likely be the largest Singapore Reit listing in a decade. Meanwhile, interior fit-out business Lum Chang Creations is looking to list on the Catalist board.
Business Times
2 days ago
- Business Times
Mystery US$33 billion Chinese medicine fortune collapses in days
[HONG KONG] When Yat-Gai Au was worth US$33 billion on paper, he was not in his Hong Kong office. One week later, when his net worth plunged to US$10.1 billion, he was not around either. Officers at the headquarters of Regencell Bioscience Holdings said both times that Au only takes short visits there, before turning away reporters. The firm, a Nasdaq-listed, Cayman Islands-incorporated traditional Chinese medicine company, occupies the whole 9th floor of a tower in Hong Kong's bustling Causeway Bay, including a reception area with a large table-tennis table. Little is still known about the tiny, money-losing company whose shares exploded 82,000 per cent higher and suddenly made Au, its chief executive officer with an 86 per cent stake, richer on paper than some of the city's tycoons like Li Ka-shing. The fleeting nature of its rip-roaring rally has captivated and mystified observers from the US to Hong Hong. Morning Brew, a popular business account on X, flagged its stock move and wondered: 'Is there something I'm missing?' Regulators in the US, which closely monitor wild swings in stock prices, might soon be asking the same question, according to experts. The Financial Industry Regulatory Authority, the watchdog for broker-dealers, has repeatedly warned that small, cheap stocks are more susceptible to fraud. These companies can be targets for pump-and-dump schemes in which fraudsters inflate the stock price and quickly sell their shares. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The US Securities and Exchange Commission, meanwhile, has been increasingly wary about companies listed on US exchanges that are based overseas – and Regencell checks both boxes. The regulator on June four called on the public to weigh in on whether the agency needed to amend the definition of what's called a foreign private issuer, potentially limiting the number of companies that qualify for special status that lets them avoid filing quarterly financial reports or disclosing when executives buy or sell company shares. 'This is an example of very unusual movements in share prices,' said Richard Harris, founder and chief executive of Port Shelter Investment Management in Hong Kong. 'These movements could certainly trigger interest by investigators.' The SEC and Finra declined to comment on whether they were monitoring Regencell's moves. Finra's mission is to protect investors and safeguard market integrity, spokesperson Rita De Ramos said. 'In line with that mission, Finra continues to monitor the market for unusual trading activity, as part of our normal course of action.' Regencell did not respond to emails and phone calls for comment on its stock performance and its founder's fortune. The company's shares have retreated 74 per cent from their peak, shrinking Au's stake to about US$8.6 billion as of Jun 26. Founded in 2014, Regencell's main line of business is marketing and licensing traditional treatments for ADHD and autism spectrum disorder developed by the founder's father, Sik-Kee Au. It has exclusive rights over his traditional medicinal formulas, trademarked under the name Brain Theory. The firm posted net losses of US$4.4 million and US$6.1 million, respectively, for the fiscal years ended June 2024 and 2023, according to filings. Its chief medical officer position has been vacant since the last doctor to hold the job resigned in 2022. The younger Au attended the Haas School of Business at the University of California, Berkeley and worked at Deutsche Bank in the late 1990s. He suffered from learning disorders and speech problems, had poor grades and an uncontrollable temper, according to a video post on the company's Instagram account. Regencell's mission is to 'improve and save lives using a natural and holistic TCM formula to treat ADHD and ASD,' according to the same video. The company's official Instagram account has more than half a million followers. BeOne Medicines Ltd., the largest healthcare firm listed in Hong Kong, has just over 2,500. Regencell built out a following with the help of social-media campaigns on the platform that offered free tickets for Taylor Swift concerts in the US and Asia. The company's second-largest shareholder is Digital Mobile Venture, a firm ultimately owned by Taiwan's Samuel Chen and his wife Fiona Chang. Chen was an investor whose early investments in Zoom Video Communications made him a fortune when the company's stock soared almost 1,500 per cent during the pandemic. Chen, Chang and their children own a 55 per cent stake in Taipei-based Polaris Group, a biotechnology company developing anti-cancer drugs. He's also the biggest shareholder of Sonix Technology, a provider of integrated circuits listed in Taipei. Bloomberg News received no reply to emails sent to Polaris and Sonix seeking comments from Chen. While monitoring for wild price swings used to be done manually, the SEC and Finra now have programmes to automatically detect market anomalies, according to Erik Gordon, professor at the University of Michigan's Ross School of Business. They can also compel companies to share if they know why their stock price soared or crashed or whether insiders cashed in at the peak. The absence of profits or revenues at Regencell isn't an automatic red flag; plenty of early-stage pharmaceutical companies have similar finances, he said. On Jun 18, two men and a woman arrived at Regencell's Hong Kong office seeking information about treatment for ADHD and dementia. They said they read about the stock's surge before arriving. The visitors were also turned away. An employee said its staff were not doctors, and directed them to the company's website. 'Early stage pharma companies can jump from a dollar to four dollars in 90 seconds if there's some news about one of their drugs under development doing well in a clinical trial,' Gordon said. In this case, 'what's interesting is there's no news.' BLOOMBERG
Business Times
2 days ago
- Business Times
Japan's NTT files billion-dollar Reit listing with MAS; IPO set to be SGX's biggest in four years
[SINGAPORE] Japanese telco Nippon Telegraph and Telephone (NTT) is spinning off some of its data centres into a Singapore-listed real estate investment trust, or S-Reit, marking what is likely to be the largest Singapore listing in four years. The last company to list at this size was the US$977 million initial public offering (IPO) of Digital Core Reit in 2021. The portfolio will comprise six of its data centre assets, initially indicated to be transferred to the Singapore Reit called NTT DC Reit for about US$1.6 billion. The initial portfolio of NTT DC Reit comprises six data centres – four located in the US, one in Austria and one in Singapore. In its prospectus lodged with the Monetary Authority of Singapore (MAS) on Friday (Jun 27), NTT said that the manager was listing as it believed there is significant growth in the global data centre market with further headroom for expansion. This includes consistent growth in data centre pricing globally, alongside increasing capacity absorption and declining vacancies as well as a surge of capital allocation into data centres alongside increasing demand and consistent pricing growth. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The IPO portfolio is also strategically diversified across key global markets, including the top 10 markets in the US and Asia-Pacific. NTT has a market capitalisation of around US$90 billion. Cornerstone investors include Singapore's sovereign wealth investor GIC, AM Squared, Pinpoint Asset Management and Ghisallo Master Fund. NTT has one of the largest global data divisions, covering more than 20 countries and regions across the Americas, Asia-Pacific, Europe, the Middle East and Africa. NTT's proposed listing comes after a subdued market in recent years, where delistings have outpaced new listings on the local bourse, with more Singapore companies choosing to list on global exchanges. It also comes after the MAS' equities market review group put forward several proposals to boost the local equity market earlier this year. The proposals by the group, which was set up last August, include introducing tax incentives to spur more listings and a S$5 billion investment fund for asset managers to improve the bourse's liquidity.
